Sun Pharmaceutical Industries Limited to acquire Organon & Co. for $11.75 billion, expanding its global footprint in women’s health, biosimilars, and established medicines.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
Sun Pharmaceutical Industries Limited has entered into a definitive agreement to acquire Organon & Co. in an all-cash transaction valued at approximately $11.75 billion, with Organon shareholders receiving $14.00 per share. The acquisition aligns with Sun Pharma’s strategy to expand its Innovative Medicines business while strengthening its position in established brands and branded generics.
Organon, formed in 2021 as a spinoff from Merck (MSD outside the United States and Canada), has a portfolio of more than 70 products across women’s health, biosimilars, and general medicines.
The company operates in 140 countries, with key markets including the U.S., Europe, China, Canada, and Brazil, supported by six manufacturing facilities across the European Union and emerging markets, and focuses on expanding access to treatments across diverse patient populations.
The combined entity is expected to rank among the top 25 global pharmaceutical companies, with revenues of approximately $12.4 billion, and will expand Sun Pharma’s presence in women’s health and enable its entry into biosimilars as a top 10 global player. The transaction is also expected to extend the company’s reach to 150 countries and strengthen its cash generation profile.
Dilip Shanghvi, Executive Chairman of Sun Pharma described the transaction as a strategic opportunity to advance Sun Pharma’s long-term vision, noting that Organon’s portfolio, capabilities, and global reach are highly complementary and could help build a more diversified and sustainable growth platform while continuing its legacy.
Kirti Ganorkar, Managing Director of Sun Pharma said the deal represents a logical step in strengthening the company’s global presence, with a focus on ensuring business continuity, disciplined integration, and responsible value creation, while highlighting opportunities to leverage Organon’s talent and realize meaningful synergies, including potential revenue growth.
Carrie Cox, Executive Chair of Organon stated that the decision followed a comprehensive strategic review and that the all-cash transaction delivers immediate and compelling value to shareholders, while positioning Organon’s business, workforce, and patient-focused mission for continued progress under Sun Pharma.
Under the terms of the agreement, Sun Pharma will acquire 100% of Organon’s outstanding shares through a merger with a subsidiary, with financing from a combination of existing cash and committed bank funding. For the year ended December 31, 2025, Organon reported revenue of $6.2 billion, supported by additional proceeds from a recent divestiture. The transaction has been approved by both companies’ boards and is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
Reference
PR-Sun-Organon-announcement-Apr-26.pdf
Sun Pharma signs Definitive Agreement to Acquire Organon | Organon
About the Writer
Samiksha Vikram Jadhav is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She specializes in pharma market research, with a focused interest in mergers and acquisitions, strategic partnerships, and global pharma and biotech deals. Her work centers on analyzing industry transactions, market positioning, and business strategies, translating complex developments into clear, accurate, and insightful scientific and commercial reporting.